Weight loss medications Ozempic and Wegovy, in particular, have been scrutinized for their high out-of-pocket costs.

Health-care companies fell as traders rotated out of a sector likely to face more regulation. President-elect Donald Trump is set to give Robert F. Kennedy Jr., his pick as Health and Human Services ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden adds Ozempic to list for Medicare price negotiationIn one of its last actions, the Biden ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Stocks rallied sharply Friday and the S&P 500 was on pace for its best week since early November.These stocks were making ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Current health news highlights include debates over Medicare pricing for drugs like Ozempic and Wegovy, management shifts ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...